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Objective
To explore the prevalence and features of HIV-associated neurocognitive disorders (HANDS) in Botswana, a
sub-Saharan country at the center of the HIV epidemic.
Design and Methods
A cross sectional study of 60 HIV-positive individuals, all receiving highly active antiretroviral therapy
(HAART), and 80 demographically matched HIV-seronegative control subjects. We administered a
comprehensive neuropsychological test battery and structured psychiatric interview. The lowest 10th
percentile of results achieved by control subjects was used to define the lower limit of normal performance on
cognitive measures. Subjects who scored abnormal on three or more measures were classified as cognitively
impaired. To determine the clinical significance of any cognitive impairment, we assessed medication
adherence, employment, and independence in activities of daily living (ADL).
Results
HIV+ subjects were impaired for all cognitive-motor ability areas compared with matched, uninfected control
subjects. Thirty seven percent of HIV+ patients met criteria for cognitive impairment.
Conclusion
These findings indicate that neurocognitive impairment is likely to be an important feature of HIV infection in
resource-limited countries; underscoring the need to develop effective treatments for subjects with, or at risk
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Objective: To explore the prevalence and features of HIV-associated neurocognitive disorders (HANDS) in Botswana, a sub-
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abnormal on three or more measures were classified as cognitively impaired. To determine the clinical significance of any
cognitive impairment, we assessed medication adherence, employment, and independence in activities of daily living (ADL).
Results: HIV+ subjects were impaired for all cognitive-motor ability areas compared with matched, uninfected control
subjects. Thirty seven percent of HIV+ patients met criteria for cognitive impairment.
Conclusion: These findings indicate that neurocognitive impairment is likely to be an important feature of HIV infection in
resource-limited countries; underscoring the need to develop effective treatments for subjects with, or at risk of developing,
cognitive impairment.
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Introduction
Botswana has one of the highest human immunodeficiency virus
(HIV) prevalence rates in the world, but it also has one of the most
comprehensive nationally organized HIV testing and antiretroviral
(ARV) therapy programs within sub-Saharan Africa [1]. Despite
the initial success in Botswana in providing comprehensive free
HIV testing and treatment with ARVs, there have been no studies
to assess possible neurobehavioral complications in HIV-positive
(HIV+) individuals on highly active antiretroviral treatment
(HAART). In this paper we present the first systematic survey
describing neurocognitive and affective functioning related to HIV
infection in a HAART-treated Batswana cohort, where cade C is
the predominant subtype.
It has been well documented that HIV enters the central nervous
system (CNS) early after infection [2,3] and that as many as 50% of
individuals with AIDS have neurocognitive impairment [4]. Even
mild neuropsychological impairment has been associated with
decreased vocational functioning, problems with medication
management, driving, and activities of daily living [5,6]. Almost
all of these data come from studies conducted in the United States
[7,8] Europe [9], and the Pacific Region/Australia [10]. Less is
known about the prevalence and characteristics of neurobehavioral
complications of HIV infection in developing African countries such
as Botswana, which carry the burden of the HIV epidemic [11–14].
Research has suggested that the incidence of HIV-associated
neurocognitive disorder (HAND) may vary due to different viral
clades. For example, in Uganda clades A and D are the
predominant subtypes, and a study found 31% of HIV+ individuals
had dementia, and 47% mild cognitive impairment [15]. An
additional study in Uganda showed that risk factors for HAND were
low CD4 cell count and advanced age [13]. In contrast, a study in
Ethiopia, which is primarily clade C, did not find cognitive
impairment on a screening measure of dementia in HIV+ subjects
compared with control subjects [12]. Another study of clade C
HIV+ subjects in several Pacific Rim countries found cognitive
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impairment (verbal fluency 33.6%), decreased fine motor speed
(finger tapping 43%), and impaired gait (28%) [10]. Similarly, a
study in southern India, with predominantly clade C HIV+ subjects,
found mild to moderate cognitive impairment in 60.5% of subjects
with no clinically identified functional impairment [16]. A study in
China indentified cognitive impairment in 34.2% of HIV+ subjects,
with cognitive impairment in 39.7% of subjects who were co-
infected with HIV and hepatitis C virus [17]. Most recently a study
in South Africa, which is also predominantly clade C, found a
prevalence of 42.4% mild cognitive disorder and 25.4% dementia in
HIV+ patients beginning anti-retroviral therapy. Risk factors
included lower levels of education, older age, and male gender [18].
While HAART has had a dramatic effect on the incidence and
severity of HAND, its milder form continues to be prevalent. This
may be due to a number of factors that include: delayed initiation
of HAART, poor CNS penetration of many ARVs, drug
resistance, potential ARV neurotoxicity, poor medication adher-
ence, side-effects of long-term use of HAART, such as cardio-
vascular disease, and chronic HIV brain infection [19,20].
Diagnosis of HAND is of great importance, not only clinically,
but also to ensure appropriate allocation of scarce medical
resources in the regions worst affected by the HIV epidemic. To
address this, the aims of the present study were twofold: 1) To
determine the prevalence of cognitive impairment in an HIV-
positive population in Botswana, a country with one of the highest
HIV rates in the world, and 2) To assess, from a neurocognitive
perspective, the effectiveness of HAART regimens with differing
CNS penetration scores for HIV-positive patients in a resource-
limited setting.
Methods
Ethics Statement
This research study was approved by the Institutional Review
Boards (IRBs) from the Botswana Ministry of Health, Princess
Marina Hospital (PMH), University of Pennsylvania, and Monash
University. Written informed consent was obtained from the
participants after the study had been fully explained to them.
HIV+ Participants: Sixty HIV+ subjects were asked to
participate. They were approached from March through August
2009 during routine follow-up visits at the Infectious Disease Care
Clinic (IDCC) at PMH in Gaborone, Botswana. A small
reimbursement ($4.00) for participation was offered. Inclusion
criteria were men and women with: (1) documented HIV-positive
status; (2) ages 21–50; (3) ambulatory status; and (4) the ability to
comprehend study procedures and provide informed consent. All
patients were prescribed HAART. Exclusion criteria eliminated
individuals with cognitive impairment unrelated to HIV, such as:
(1) neurological conditions (e.g. head injury, seizure disorder); (2)
chronic medical illness unrelated to HIV (e.g. chronic hepatic or
renal failure, malignancy) or severe HIV-related disease (current
opportunistic infection); (3) current fever; (4) severe psychiatric
disorder (e.g. schizophrenia); (5) a history of substance abuse; (6)
sensory impairment (e.g. deafness) that would impede understand-
ing of test directions; or (6) inability to function independently as
assessed using the study instruments.
Control Subjects
Eighty demographically matched HIV-negative (HIV-) individ-
uals who met the inclusion/exclusion criteria, also agreed to
participate. All controls received a negative ELISA HIV test on
the day of neurobehavioral testing, and were recruited from
Tebelopele Voluntary Counseling and Testing Centre (TVCTC),
a free government sponsored HIV testing centre adjacent to PMH.
Procedure
Subjects underwent a standardized neuropsychological exami-
nation, a structured psychiatric interview of depression/anxiety,
and an assessment of activities of daily living (ADL). Assessments
were in the preferred language (Setswana or English) for each
subject, administered by a Motswana medical student fluent in both
languages (K.J.) or a neuropsychologist from the University of
Pennsylvania (K.L.). Testing procedures were standardized for these
two examiners. The neuropsychologist thoroughly trained and
closely supervised the medical student. All consent forms, question-
naires, and tests were translated into Setswana and back translated.
For patients with limited reading ability, the ADL scale was
administered orally by the examiners. The investigators evaluated
neuropathy using a targeted history composed of structured
validated questions designed to elicit symptoms of distal sensory
loss or pain. Structured interviews and chart reviews were
performed to obtain information about medical and psychiatric
history, pattern of substance use, adherence to ARV medication,
marital status, education, employment, current medications,
current and nadir CD4 lymphocyte counts, and viral loads. The
assay used for viral load testing in Botswana is the Amplicor HIV-1
Monitor Assay, Roche Molecular Systems, Branchburg, New
Jersey. The lower limit of detection of the assay is 400 copies/
mL. Viral loads were categorized dichotomously as detectable
(.400 copies/ml) versus undetectable (,400 copies/ml).
Measures
The neuropsychological test battery assessed six cognitive-motor
ability areas: processing speed, psychomotor speed, verbal
learning/memory, executive function, language, and fine motor
speed. Research has shown that these ability areas are consistently
affected by HAND in developed countries [21–23] and more
recently in several resource-limited countries [14,16,17,24–26].
This battery was primarily made up of tests that have been widely
used to study HIV infection in the United States, Europe, and
multi-national studies in developing regions [19,23]. In addition,
we included a modified auditory verbal learning test, The
Botswana Auditory Verbal Learning Test (BAVLT). This test
was designed for administration in either Setswana or English, and
is more appropriate for use in Botswana than existing verbal
learning tests [27].
Participants underwent structured psychiatric interviews to
assess major depressive disorder (MDD), generalized anxiety
disorder (GAD), and alcohol use. To explore the clinical
significance of neuropsychological impairment, we assessed
independence in activities of daily living (ADL), employment
status, and adherence to ARV regimens.
Digit Symbol Coding (DSC) sub-test of the WAIS-III [28]
The DSC is a paper-pencil measure of processing speed.
Subjects use a key of digit-symbol pairs at the top of the test page
and are required to fill in the correct symbol for each number as
quickly as possible within a 120 second time limit. The score is the
number of correct symbols transcribed within the time limit.
Verbal Fluency for Action
Action fluency (AF) is a test of language that taps into frontal
neural systems [29] and has been shown to be sensitive to the
neurocognitive effects of HIV infection in subjects in both
developed and resource-limited countries [30]. This task requires
subjects to generate as many action words (verbs) as they can
within a time limit. The score is the total number of correct words
produced within one minute.
Neurobehavior of HIV in Botswana
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Botswana Auditory Verbal Learning Test (BAVLT)
The BAVLT [27] is similar to other verbal learning tests, including
the WHO/UCLA Auditory Verbal Learning Test, which has been
shown to be sensitive to HIV in several developing countries
[16,22,31]. The BAVLT is a list-learning task, composed of 16 words
from 4 categories, and an interference word list (16 different words, 4
different categories). This test has both immediate and thirty-minute
delay free recall trials, and a recognition trial. Words were carefully
selected so that they would be familiar to all Batswana, even subjects
with minimal or no education, and translated easily between
Setswana and English. Scores analyzed included the total number
of words learned for the 5 trials (TL), immediate free recall (IR),
delayed free recall (DR), and recognition (R).
Trail Making Test A [32]
The Trail Making Test A (TA) assesses psychomotor speed,
attention, sequencing, and visual scanning efficiency. This task
required participants to connect numbered circles, randomly
scattered over a sheet of paper, sequentially from 1 to 25. The
score is the time taken to correctly connect the numbered circles.
Color Trails 2 (CT2) [33]
In addition to the skills required for Trail Making Test A, this
test also assesses set-shifting ability. To minimize cultural bias, no
letters or written instructions are used. It consists of numbered
colored circles from 1 to 25, in bright yellow and pink. Each
number is represented twice, once in each color. Using a pencil the
subject is required to connect the numbers sequentially, while
alternating between the two colors. The score is the time taken to
correctly connect the numbered circles.
Grooved Peg Board Test (GPT)
This test measures fine motor speed and manual dexterity for
each hand. Subjects were required to insert small grooved pegs
into matched holes on a board. Each hand is tested separately and
the score is the time taken to correctly place all of the pegs [34].
Primary Care Evaluation of Mental Disorders (Prime-MD)
[35]
Three modules were administered from the Prime-
MD. Mood Module (MM): The MM is a focused interview, that
follows DSM-IV criteria [36], for screening medical patients for
current depression, composed of simple ‘‘yes’’ and ‘‘no’’ questions.
If five or more of the nine symptoms are present and one of these
symptoms is sadness/hopeless or anhedonia, then a diagnosis of
MDD is supported. The MM has been successfully used to
diagnose depression in patients with HIV and was found to have a
sensitivity of 77% and specificity of 84% [37]. In addition, it was
previously validated in HIV+ Batswana individuals [38].
Generalized Anxiety Module (GAM): The Generalized Anxiety
Module consists of 7 simple ‘‘yes’’ and ‘‘no’’ questions aimed at
diagnosing Generalized Anxiety Disorder. Subjects must acknowl-
edge feeling anxious and have three or more symptoms of anxiety
to meet DSM-IV criteria for a Generalized Anxiety Disorder.
Alcohol Module (AM): This inventory is composed of six ‘‘yes’’ and
‘‘no’’ questions about alcohol use during the past six months,
aimed at gauging how much alcohol has interfered with activities
such as relationships, school/work, and driving. The higher the
score, the more alcohol has interfered with daily responsibilities.
Activities of Daily Living Scale (ADL)
This questionnaire was selected for its wide use and demon-
strated validity in studies of medically ill and dementia popula-
tions, including HIV subjects in developing countries [39]. It is a
14-item scale measuring physical self-maintenance (e.g., dressing,
bathing) and instrumental activities of daily living (e.g., preparing
meals, taking medications). Each item is rated on a four-point
scale: (1) no difficulty at all; (2) has some difficulty; (3) needs some
assistance; (4) can’t do at all. Higher scores indicate more
impairment in daily functioning.
Data Analysis. We performed descriptive analyses and
comparisons to examine the demographic and clinical character-
istics of patients. All analyses were conducted using StataMP 10.0
(College Station, TX). Correlation coefficients were used to assess
relationships between continuous variables. Student’s t-test and
analysis of variance (ANOVA) were used for comparisons of normally
distributed variables. Kruskal-Wallis rank was used for non-normal
variables, and Fisher’s exact tests and Chi2 tests were used for
categorical variables. Variables were transformed to normality, as
possible. The relative differences in cognitive impairment between
the HIV+ and HIV- groups, adjusted for demographic (age, gender,
education, and opportunistic infection) and HIV characteristics
(nadir/current CD4 count, time since beginning HAART, a detect-
able viral load), was assessed using regression models. As this was an
exploratory study, alpha was set at 0.05 to determine statistical
significance. Additionally, the study was designed to detect differences
between HIV+ and HIV- subjects in continuous cognitive impair-
ment measures of at least 0.5 standard deviation units.
Results
The two groups were comparable in age, education, and gender
distribution (Table 1). HIV+ patients were more likely to be
married whereas HIV- controls were more likely to have chosen to
do the study test in Setswana. All of the HIV+ patients were
prescribed HAART, having met criteria for HAART initiation as
defined in the Botswana National HIV Guidelines [40], and none
of the HIV- participants were prescribed HAART.
Laboratory Characteristics
These are summarized in Table 2. Nadir CD4 counts were
unavailable for eight HIV+ subjects, so analyses between
laboratory values and neuropsychological measures excluded
them. Nadir CD4 count was not associated with cognitive
impairment (p = 0.3), nor was current CD4 count (p = 0.3).
Furthermore, nadir CD4 count was not associated with depression
(p = 0.5), anxiety (p = 0.3), or difficulty with ADL (p = 0.14).
Similarly, current CD4 count was not associated with any of these
measures (depression p.0.99, anxiety p = 0.2, ADL p = 0.12).
Ninety-three percent of subjects in our sample had an
undetectable viral load (i.e. viral load was ,400 copies/mL).
Thus, it was not feasible to analyze the data as a continuous
outcome. Viral load was therefore examined as a dichotomous
outcome (detectable versus undetectable). We found no association
between viral load and any of depression, anxiety, or ability to
perform ADL, even at a bivariate level.
Neuropsychological Performance for HIV+ and HIV-
Subjects
Table 3 summarizes raw scores (means and standard deviations)
on the neuropsychological tests, and also indicates effect sizes
comparing the HIV+ group to the uninfected group, adjusted for
the effects of age, education, gender, and history of opportunistic
infection. Mean t-scores for the neuropsychological tests all
showed significant group effects. The HIV+ group was signifi-
cantly impaired compared to the HIV- group on measures of
processing speed (DSC, p,0.01), verbal learning and free recall
Neurobehavior of HIV in Botswana
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memory (BAVLT: TL p = 0.01, IR p,0.01, DR p,0.01), but not
recognition (R p = 0.64). HIV+ subjects made more errors on the
BAVLT, which included false positive (p,0.01) and intrusion
errors (p = 0.01).
The HIV+ group was also impaired when assessing fine motor
speed/dexterity in both dominant (D/GPB, p = 0.04) and non-
dominant hands (ND/GPB, p = 0.01), psychomotor speed (TA,
p = 0.01), executive functioning (CT2, p,0.01), and language (AF,
p,0.01).
Association Between Neuropsychological Impairment,
Alcohol Use and Psychological Measures (Anxiety/
Depression)
There was no difference between the two groups with respect to
alcohol use (p = 0.6). Subjects in both groups reported very
minimal use of alcohol and virtually no participants reported
current substance abuse.
Forty-two percent of HIV+ subjects met criteria for Generalized
Anxiety Disorder (GAD), which was higher than the 25% in
controls (p = 0.04). In contrast, incidence of Major Depressive
Disorder (MDD) was similar for the two groups (HIV+ 35%,
HIV2 28.8%, p = 0.5), as was level of suicidal ideation (HIV+
15%, HIV2 7.5%, p = 0.18). There was no difference in
neuropsychological performance for depressed (n = 96) and non-
depressed subjects (n = 44). These findings will be described in
detail elsewhere.
Definition of Cognitive Impairment and Association with
other Factors
According to recently updated research definitions of HAND,
Asymptomatic Neurocognitive Impairment (ANI) is defined by
performance at least 1 SD below the mean of demographically
adjusted normative scores in at least two cognitive areas, with at
least 5 cognitive domains measured. Criteria for ANI also require
that the impairment: does not occur solely as part of delirium,
cannot be explained by other co-morbidities, pre-existing
conditions, depression, or substance abuse, and does not interfere
with everyday functioning [4]. To be consistent with this definition
while account for some non-normality in results achieved by
control subjects on grooved peg board testing, the lowest 10th
Table 1. Demographic Characteristics of Subjects.
DEMOGRAPHIC
CHARACTERISTICS
HIV- CONTROL
SUBJECTS
(N = 80)
HIV+
SUBJECTS
(N = 60)
P-
VALUE
Age in years (SD) 35.8 (6.7) 37.5 (6.2) 0.11
Total education in years (SD)
No education
Primary
Secondary
Post-Secondary
9.3 (4.2)
10%
18.8%
58.8%
12.5%
8.6 (4.2)
13.3%
20%
51.7%
15%
0.24
Gender (% male) 50% 48.3% 0.87
Marital status:
Single
Married
79.7%
20.3%
58.3%
41.7%
0.01
Employment status:
Employed
Unemployed
Months worked in last year
77.5%
22.5%
8.7 (4.9)
71.7%
28.3%
7.6 (5.2)
0.44
0.13
Language of test administration:
Setswana
English
Both
78.8%
17.5%
3.8%
61.7%
36.7%
1.7%
0.03
doi:10.1371/journal.pone.0017233.t001
Table 2. Clinical and Laboratory Characteristics of 60 HIV
Infected Subjects (Mean scores and standard deviations in
parentheses).
LABORATORY
CHARACTERISTICS PERCENT MEAN
STANDARD
DEVIATION RANGE
Current CD4 count 416.4 198.5 82.0–955.0
Subjects with current
CD4,200 15%
Nadir CD4 97.6 49.9 4.0–186.0
Time since HIV
diagnosis (years)
4.6 2.5 0.5–15.1
Viral Load:
,400
.400
93.3%
6.7%
On HAART (.3 drugs) 100%
HAART treatment
duration (years)
4.1 2.1 0.1–10.8
Self-reported
adherence as ‘‘always’’
78.3%
Peripheral neuropathy 40%
Prior opportunistic
infections:
TB
Syphilis
35%
22%
doi:10.1371/journal.pone.0017233.t002
Table 3. Performance on Neuropsychological Measures.
CONTROLS
(N = 80)
HIV+
(N = 60)
P-
value
NEUROPSYCHOLOGICAL MEASURES
Processing Speed:
Symbol Digit Coding (SDC)
52.4 (16.1) 40.8 (17.5) ,0.01
Verbal Learning/Memory (BAVLT):
Total Words (T)
Immediate Recall (IR)
Delayed Recall (DR)
Recognition (R)
Intrusion Errors (Total)
False Positive Recognition Errors
54.3 (12.02)
12.1 (2.2)
12.4 (2.3)
15.3 (0.9)
2.7 (4.2)
1.5 (2.8)
48.4 (14.84)
9.8 (2.3)
10.2 (2.8)
14.8 (2.2)
4.4 (5.3)
2.8 (3.5)
0.01
,0.01
,0.01
0.64
0.01
,0.01
Fine Motor Speed/Dexterity (GPB):
Dominant Hand Time (seconds)
Non-dominant Hand Time (seconds)
80.2 (21.7)
88.0 (16.8)
86.4 (25.1)
102.5 (38.1)
0.04
0.01
Executive Functions:
Color Trails 2 (CT2, Time in seconds)
Color Trails 2 (Errors)
123.7 (60.10)
0.4 (0.9)
164.9 (98.4)
0.9 (1.5)
,0.01
0.03
Language:
Action Fluency (AF, Total Words) 11.6 (3.8) 9.3 (3.9) ,0.01
Psychomotor Speed:
Trail Making Test A (TA, seconds) 52.6 (23.9) 68.7 (38.5) 0.01
PSYCHOLOGICAL MEASURES
PRIME-MD
Major Depressive Disorder
Suicidal Ideation
Generalized Anxiety Disorder
28.8%
7.5%
25%
35%
15%
41.7%
0.47
0.18
0.04
Raw scores, means, standard deviations (in parentheses), and effect sizes on
individual neuropsychological test measures for HIV+ and HIV- subjects.
doi:10.1371/journal.pone.0017233.t003
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percentile of results achieved by HIV- control subjects was defined
as the lower limit of normal performance for the six cognitive-
motor measures studied here. Lower performance than this on at
least 3 tests (and thus at least two cognitive areas) was defined as
impaired to at least the level of ANI. A substantial number of
HIV+ subjects tested as cognitively impaired using this definition.
Thirty seven percent of HIV+ subjects scored impaired on three or
more measures and were defined as cognitively impaired (Table 4).
Univariate analysis revealed that cognitive impairment was
associated with increasing age, fewer years of education and
having been married. Cognitive impairment was not associated
with number of years since HIV diagnosis, CD4 count (current or
nadir), neuropathy, depression, medication adherence, or alcohol
use (Table 5). Multivariate analysis demonstrated, among HIV+
patients, fewer years of education (p = 0.007) and older age
(p = 0.002) were independently associated with cognitive impair-
ment (See Table 6).
HAART Regimen and Cognitive Function Among HIV+
Subjects
All HIV+ subjects were on HAART and drug regimens were
recorded for 95% of subjects. Seventy-eight percent of patients
were on standard first line regimens consisting of two nucleoside
(or nucleotide) analog reverse transcriptase inhibitors (one of
Zidovudine, Tenofovir or, Stavudine, together with either
Lamivudine or Emtricitabine), and either a non-nucleoside analog
reverse transcriptase inhibitor (Nevirapine or Efavirenz), or a
protease inhibitor (ritonavir-boosted Lopinavir). In addition, two
patients were using Abacavir as a fourth drug. Seventeen percent
of patients were using second line therapy, which in all cases
consisted of zidovudine, lamivudine and lopinavir/ritonavir. Each
drug was given a CNS penetration score [41] to determine
whether the total CNS penetration score of the regimens was
associated with cognitive impairment. Antiviral drugs with high
ability to penetrate the blood-brain barrier were given a
penetration score of 1 (nevirapine, lopinavir/ritonavir, abacavir,
zidovudine), drugs with intermediate ability were given a score of
0.5 (stavudine, lamivudine, emtricitabine, efavirenz), and poor
ability was scored 0 (tenofovir). The mean penetration score of
HAART regimens used by patients was 2 (range 0.5–3.5). There
was no difference (p = 0.6) in CNS penetration scores for patients
who were cognitively impaired and patients who were not
cognitively impaired (Table 5)
Activities of Daily Living, Adherence, and Employment
Slightly over 21% of HIV+ subjects reported difficulty adhering
to ARV regimens, which they attributed exclusively to memory
difficulties. Subjects who reported problems with adherence did not
differ on any of the demographic variables of age (p = 0.2),
education (p = 0.5), gender (p = 0.2), or marital status (p.0.99).
Despite subjective complaints of difficulty remembering to take
medication, these subjects were not more impaired on objective
memory measures on the BAVLT than patients reporting high
levels of medication adherence (TL p = 0.8, IR p = 0.4 DR p = 0.7).
Details of the ADL results are described in detail elsewhere.
Discussion
There are two main findings in this study. First, HIV+ subjects
were impaired on neuropsychological measures when compared to
Table 4. HIV+ Subjects Impaired on Neuropsychological
Measures.
NEUROPSYCHOLOGICAL MEASURE CUT OFF IMPAIRED*
Processing Speed: Digit Symbol Coding 32 32%
Memory: Delayed Recall (BAVLT) 9 37%
Language/Verbal Fluency:
Action Fluency
7 38%
Psychomotor Speed: Trails A 78.5 30%
Executive Function: Color Trails 2 221.5 20%
Fine Motor Speed: GPB Dominant Hand 100 22%
Fine Motor Speed:
GPB Non-dominant Hand
108.5 25%
Cognitive Impairment .3 impaired
scores
37%
The lower 10th percentile of results achieved by HIV- control subjects was
defined as the lower limit of normal performance for 6 cognitive tests and 2
measures of fine motor speed. *Lower performance than this was defined as
impaired. HIV+ subjects who scored impaired on three or more tests were
defined as cognitively impaired. The cut off results used to differentiate normal
and impaired performance are shown here.
doi:10.1371/journal.pone.0017233.t004
Table 5. Characteristics of Impaired and Non-Impaired HIV+
Subjects.
HIV+ PATIENT
FACTORS
IMPAIRED
(N = 22)
NON-
IMPAIRED
(N = 38) P VALUE
Age 42 (6.1) 34.8 (4.5) ,0.0001
Education (years) 5.8 (4.1) 10.3 (3.4) ,0.0001
Employment (Full-Time) 16 (73%) 19 (50%) 0.1
Never Married 15 (68%) 34 (89%) 0.04
Neuropathy 8 (36%) 16 (42%) 0.7
Alcohol Use 4 (18%) 8 (21%) 0.8
Years Since HIV Diagnosis 4.6 (1.6) 4.6 (2.9) 0.9
Nadir CD4 (range in
parentheses)
109
(4–415)
137
(4–453)
0.1
Current CD4 373
(175–713)
442
(82–955)
0.3
Detectable Virus 2 (9%) 2 (5%) 0.6
Years on HAART 4.4 (1.7) 3.9 (2.3) 0.3
Depression 7 (32%) 14 (37%) 0.7
Non-Adherence 3 (14%) 10 (27%) 0.3
CPE Score 1.95 (0.49) 2.01 (0.62) 0.6
Univariate analysis of associations between patient factors and cognitive
impairment for HIV+ subjects, defined as impaired and non-impaired. Mean
scores/years and standard deviations (in parentheses).
doi:10.1371/journal.pone.0017233.t005
Table 6. Logistic regression model of factors independently
associated with cognitive impairment in this cohort.
Variable Odds ratio
95% Confidence
interval p value
Age in years 1.28 1.1, 1.49 0.002
Years of education 0.76 0.62, 0.93 0.007
(Model R2 = 0.40, p,0.0001).
doi:10.1371/journal.pone.0017233.t006
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demographically matched controls for all cognitive-motor ability
areas, which included processing speed, verbal learning/memory,
language, psychomotor speed, executive function, and fine motor
speed (dominant and non-dominant hands). Using a definition of
impairment as scoring below the 10th percentile of results achieved
by control subjects on three or more measures of cognition and/or
fine motor speed, a significant proportion (37%) of HIV+ subjects
were cognitively impaired. Second, there was no difference in CNS
penetration scores for impaired and non-impaired HIV+ subjects,
but those who were cognitively impaired were older and had less
education than subjects who were not cognitively impaired.
This study has several limitations, which include a relatively
small sample size, the use of a symptom scale to identify peripheral
neuropathy rather than a neuromedical assessment, and an ADL
scale that may not have been sensitive to detect subtle changes in
activity levels in this Batswana cohort.
The prevalence of cognitive impairment (37%) is similar to prior
research, which used the International HIV Dementia Scale (IHDS)
and found 38% of HIV+ Batswana subjects, 97.5% of whom were
on HAART, to be cognitively impaired [27]. We had anticipated
that cognitive impairment would be associated with regimens with
lower CNS penetration scores since prior studies have demonstrated
that regimens with higher CNS penetration scores are associated
with better control of CNS viral load [41] and better cognitive
outcomes [42]. But there was no difference in CNS penetration
scores between HIV+ impaired and unimpaired subjects.
All of the HIV+ subjects were prescribed HAART, which was
expected to suppress HIV viral loads and improve current CD4
counts. Most patients had undetectable plasma HIV viral loads.
Thus we hypothesized that neuropsychological status would be
related to nadir CD4, but not current CD4. The results did not
confirm this, and neither lower nadir nor current CD4 T-cell
counts were a risk factor for cognitive impairment. It is possible
that CD4 count (nadir and current) was not associated with
cognitive impairment because most subjects in this study had
achieved normal or near-normal CD4 counts, and subjects with a
known history of CNS opportunistic infections were excluded.
In the current study, older age and fewer years of education
within HIV+ subjects were associated with cognitive impairment.
A recent study of HAND in South Africa also found a significant
association with lower levels of education and older age [18].
Future large scale studies of healthy Batswana with diverse ages
and educational backgrounds will be needed to develop norms that
can be used to confidently classify HIV-related impairments in
individual cases.
Verbal learning and free recall memory were impaired for
HIV+ subjects, but recognition memory was not. This is consistent
with prior studies showing impaired free recall due to a retrieval
deficit, but intact recognition memory [43]. Qualitatively, HIV+
subjects demonstrated executive dysfunction on the BAVLT, as
illustrated by more intrusion and false positive errors, which is
reflective of the frontal-striatal brain damage that is typical of
HIV. This pattern of impairment is in agreement with previous
studies in sub-Saharan Africa [13,14,44].
From prior work in the same setting, we anticipated a relatively
high prevalence of depression in HIV+ individuals [38]. However,
we were surprised by the similarly high level of depression and
suicidal ideation in the demographically matched, uninfected
control group. The double rate of suicidality in HIV+ subjects is
clinical meaningful, but the study lacked the power to find it
statistically significant. These data suggest that depression is
common in both HIV+ and HIV- adults in this setting and that
HIV infection itself may not be the explanation (or the only
explanation) for the high rate of depression previously described in
HIV+ adults in Botswana. It has been suggested that rapid
changes in Batswana society have contributed to the high rate of
depression and suicide [45]. This includes changes in gender roles
as women have gained access to education, a decrease in marriage,
and employment patterns that have led to a steady migration away
from the traditional patriarchal family structure to a more isolated
life-style in urban settings.
HIV+ subjects did not report difficulty with routine daily
activities on the ADL scale, and were as likely to be employed as
the HIV- control subjects. One possible explanation for this is that
the neuropsychological deficits do not have the same relevance to
everyday activities for HIV+ individuals in Botswana, as compared
to US studies where even mild cognitive impairment has been
shown to adversely impact vocational activities [6]. An alternative
explanation is that the ADL scale used in this study may not be
valid in developing countries, such as Botswana, where people
have very different educational, cultural, and linguistic back-
grounds from those in the United States, Europe, and Australia.
Other researchers have pointed out that until more culturally
appropriate ADL measures have been validated for a particular
population, it may be more reliable to focus on objective
neuropsychological test performance, especially for comparison
across international settings [23]. HIV-related changes in cognitive
ability may be much less likely to cause obvious functional decline
in cultures that have fewer demands on such cognitive abilities [4].
Thus the addition of an asymptomatic category of neurocognitive
impairment, such as ANI, may be particularly important in these
types of settings to prevent such cases of cognitive impairment
from being missed. The recognition of mild cognitive impairment
in asymptomatic individuals may encourage more frequent
neurologic follow-up for individuals of ANI, help with decisions
related to the initiation of ARVs independent of biomarkers, and
guide the selection of ARV regimens.
In conclusion, neuropsychological impairment in this Batswana
sample was associated with HIV infection, and the pattern was
similar to neuropsychological studies previously carried out in
developed and developing countries, including sub-Saharan
Africa. Within the HIV+ group, those who met criteria for
cognitive impairment were older and had less education than
patients who were not cognitively impaired. These findings
indicate that HAND is likely to be important among HAART-
treated HIV individuals in developing countries.
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